Much of the conversation at THT revolved around how use of the device would be handled outside of specialized centers.

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

While researchers are grateful they can offer patients one of the two approved stabilizers, better therapeutics are still ...

Using the BiovitalsHF software to personalize recommendations got more patients on all four pillars of therapy.

Not everyone agrees: one expert says it would be more helpful to consider imaging as a quality measure at the local level.

The writing committee says collaborative efforts and patient-level perspective can improve management of pain in this ...

Sreek Vemulapalli and Roseann White explain the statistical challenges that can arise while collecting longer-term follow-up data during clinical trials.

The main results of the SUMMIT trial, reported last year, showed that tirzepatide—a dual glucose-dependent insulinotropic ...

The findings are disappointing, but questions around intervention timing, patient population, and others remain to be ...

The results increase “my confidence that this approach has merit,” Lauren Sansing says. More trials are on the way.

These early data are reassuring, but there are many questions yet to be explored in the upcoming pivotal trial, Nancy ...

The data are observational but intuitive, say experts. Further work might define where T-TEER’s greatest benefit lies.